<DOC>
	<DOCNO>NCT01995032</DOCNO>
	<brief_summary>The purpose study show intake L-citrulline metformin improve muscle function delay progression patient Duchenne 's muscular dystrophy .</brief_summary>
	<brief_title>L-citrulline Metformin Duchenne 's Muscular Dystrophy</brief_title>
	<detailed_description>This single center , randomize , double-blind , placebo control study . The study medication consist L-citrulline metformin , respectively placebo give orally ; 2.5 g L-citrulline placebo give 3 time daily , metformin contain 250 mg placebo administer 3 time daily . The duration study 26 week comprehend one screening three study visit .</detailed_description>
	<mesh_term>Muscular Dystrophies</mesh_term>
	<mesh_term>Muscular Dystrophy , Duchenne</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Molecular diagnosis DMD Patients 7 10 year age time screen Ambulant Ability walk 150 6 min walk distance ( 6MWT ) D1 subdomain MFM scale &gt; 40 % stable treatment steroid &gt; 6 month steroid na√Øve patient Previous ( 3 month less ) concomitant participation another therapeutic trial Use Lcitrulline , Larginine metformin within last 3 month Known individual hypersensitivity Lcitrulline metformin know suspected malignancy Other chronic disease clinical relevant limitation renal , liver , heart function accord discretion investigator start cortisone treatment change dosage &lt; 6 month prior screen</criteria>
	<gender>All</gender>
	<minimum_age>7 Years</minimum_age>
	<maximum_age>10 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Duchenne 's muscular dystrophy</keyword>
	<keyword>DMD</keyword>
</DOC>